Outlook is neutral, with stock confined to a range of ±4%
Strategy has +47% ROI potential and 104% overvalued
NVO 47.60+4.26 (+9.8%)Novo Nordisk A/S
NVO Novo Nordisk A/S46.40+3.06 (+7.1%)
Outlook is neutral, with stock confined to a band of ±3%
Strategy has +100% ROI potential and 86% overvalued
NVO Novo Nordisk A/S43.49-3.70 (-7.8%)
NVO 43.49-3.70 (-7.8%)Novo Nordisk A/S